Recurrent or Metastatic Solid Tumors
2 competing products in clinical development for Recurrent or Metastatic Solid Tumors.
Pipeline by Phase
Phase 11
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ifinatamab deruxtecan | Daiichi Sankyo | Phase 2 | Recruiting | 42 |
| Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 1 | Recruiting | 36 |